CIR (CIR) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
5 Aug, 2026Executive summary
Consolidated revenues reached €913.5 million in H1 2026, up 1.7% year-over-year, with 68% generated abroad, driven by KOS's 4.3% growth and stable Sogefi performance.
Net profit rose to €18.6 million from €14.5 million in H1 2025, mainly due to improved operating results and the full consolidation of KOS.
Major strategic moves included the €220–221.4 million acquisition of the remaining 40.23% of KOS, making it wholly owned, and €25.4 million in share buybacks.
Sogefi completed the sale of its Precision Springs business for €21 million, with benefits to be realized in H2 2026.
Operating performance improved, supported by higher financial portfolio income.
Financial highlights
Group revenues reached €913.5 million in H1 2026, up from €898.4 million in H1 2025.
EBITDA increased to €142.1 million (15.6% margin), and EBIT to €57.5 million (6.3% margin), both stable or slightly improved year-over-year.
Net financial position shifted from +€220.4 million at Dec 2025 to -€24.7 million at June 2026, mainly due to the KOS acquisition and share buybacks.
Net debt including IFRS 16 rose to €790.1 million from €558.8 million at year-end 2025.
Free cash flow before IFRS 16 was €21.0 million, up from €12.6 million in H1 2025.
Outlook and guidance
KOS expects continued strong demand and improved profitability in Italy and Germany, with tariff increases in rehabilitation to impact from H2 2026 and full effect from 2027.
Sogefi anticipates a low single-digit revenue decline for 2026, with adjusted EBIT margin stable and cautious outlook due to global auto market uncertainty and raw material price volatility.
Group net income for 2026 is expected to exceed 2025 levels barring extraordinary events.
Occupancy rates in Italy are near capacity, while Germany has upside potential as some regions lag.
Latest events from CIR
- EBITDA and EBIT margins improved as KOS grew and Sogefi faced headwinds.CIR
H2 2025 - Operating margins improved, but net income fell as one-off gains were not repeated.CIR
H1 2025 - Net profit soared to €114.3M in H1 2024, driven by asset sales and strong healthcare growth.CIR
H1 2024 - Net income surged to €132.2M on asset sales and margin gains; share buybacks boosted equity.CIR
H2 2024